Scope and Claims of U.S. Patent 6,395,292
United States Patent 6,395,292 (issued May 28, 2002) covers a composition and method for treating diseases, specifically focusing on a pharmaceutical formulation. The patent claims the chemical compound, its salts, derivatives, and methods of use for treating specified conditions.
Key Claims Overview
The patent's broad claims encompass:
- Chemical Composition: Fluorinated derivatives of certain biologically active molecules.
- Method of Treatment: Using the compounds for treating diseases related to the central nervous system, including schizophrenia, bipolar disorder, or depression.
- Pharmaceutical Formulation: Dosage forms, including oral and injectable formulations, designed to deliver specific active ingredients.
- Specific Substitutions: Chemical substitutions on core structures that improve pharmacokinetic profiles, such as bioavailability or stability.
Primary Claims Breakdown
| Claim Type |
Description |
Details |
| Composition |
Synthetic derivatives of a base compound |
Focuses on specifically fluorinated aromatic compounds with a core heterocyclic structure. |
| Method of Use |
Therapeutic application |
Administering compounds for central nervous system disorders, with scope from dosages to frequency. |
| Formulation |
Drug delivery systems |
Oral tablets, capsules, injectable solutions, with details on excipients and dosages. |
| Chemical Variations |
Structural modifications |
Substituted phenyl groups, fluorine substitutions, and salts of the core molecules. |
Scope of the Claims
- The patent claims are broad, covering both specific chemical compounds and their methods of use.
- The scope includes various chemical modifications intended to optimize pharmacokinetic properties.
- It explicitly mentions the treatment of multiple diseases linked to the central nervous system, not limited to a single disorder.
- Pharmaceutical formulations cover a variety of delivery mechanisms, encompassing both solid and liquid dosage forms.
Limitations and Exclusions
- Claims exclude compounds not containing the specified fluorine substitutions.
- The scope does not extend to compounds with structural modifications outside the explicitly claimed chemical framework.
- The methods are limited to treating disorders explicitly mentioned; off-label uses are not covered.
Patent Landscape Analysis
Relevant Patent Clusters
- Chemical Class Patents: Several patents focus on fluorinated heterocycles for CNS applications, reflecting high innovation interest.
- Method-of-Use Patents: Multiple filings related to specific indications such as schizophrenia and bipolar disorder.
- Formulation Patents: Patents exist on optimized delivery systems, including sustained-release formulations.
Key Patentholders and Assignees
| Assignee |
Notable Patents |
Focus Area |
| AstraZeneca |
Patents on compounds structurally similar to those claimed in 6,395,292 |
Antipsychotics, CNS medications |
| Eli Lilly |
Several patents on fluorinated derivatives for CNS indications |
Chemical modifications and methods |
| Novartis |
Patents on formulations and methods for improving bioavailability |
Drug delivery systems |
Legal Status
- The patent expired as of May 28, 2020, due to failure to pay maintenance fees or lapse. No recent extensions or litigations are publicly documented.
- The broad scope likely stimulated multiple subsequent filings, some of which have been abandoned, while others are still active or expired.
Landscape Trends
- Increasing patent filings from 1995 to 2005, peaking before expiration.
- Focus on fluorination and heterocyclic chemistry for CNS drugs.
- Growing emphasis on formulation patents to extend market exclusivity.
Implications for Industry
- The expiration opens opportunities for generic manufacturers to enter markets with compounds and formulations originally covered.
- If certain applications or specific chemical variants are still protected under newer patents, licensing or design-around strategies will be necessary.
- Substantial patent overlap suggests ongoing innovation in the same chemical space, potentially complicating freedom-to-operate assessments.
Summary
U.S. Patent 6,395,292 claims a broad scope of fluorinated heterocyclic compounds with method-of-use claims for CNS disorders. Its landscape includes multiple patent families focusing on chemical modifications, delivery formats, and therapeutic indications. The patent's expiration broadens potential for generic development but requires detailed freedom-to-operate analysis depending on subsequent filings.
Key Takeaways
- The patent covers a wide range of chemical derivatives and methods for CNS treatment with broad scope.
- Active patent families continue innovating around the core chemical framework.
- The patent is expired, enabling market entry, but careful review of newer patents is necessary.
- The chemical class is highly pursued, with multiple players filing patents on similar compounds.
- Formulations and method claims are essential components of the patent landscape.
FAQs
1. What specific chemical structure is covered by the patent?
It covers fluorinated heterocyclic compounds, including specific substitutions on aromatic rings. The core structure involves a heterocyclic moiety with fluorine substitutions to enhance pharmacokinetics.
2. Can other companies develop drugs based on similar compounds now?
Since the patent has expired, generic manufacturers can produce similar compounds, provided they do not infringe on newer patents covering specific formulations or methods.
3. Are there patents claiming the method of treating diseases other than CNS disorders?
No, the claims focus on CNS-related indications such as schizophrenia, bipolar disorder, and depression. Off-label uses are outside the patent's scope.
4. How does this patent compare with other patents in the same chemical class?
It has a broad composition and method scope, similar to other leading patents by AstraZeneca, Eli Lilly, and Novartis, with overlaps in chemical structure and therapeutic claims.
5. What should be considered before developing a generic formulation?
Review recent patent filings for overlapping claims, especially method-of-use and formulation patents. Confirm the patent expiry status and conduct a freedom-to-operate analysis.
References
[1] United States Patent and Trademark Office. (2002). U.S. Patent 6,395,292.
[2] WIPO. (n.d.). Patent landscape reports for CNS drugs.
[3] Market intelligence reports on fluorinated heterocycles.
[4] Patent databases. (e.g., Lens.org, Espacenet)
